Teclistamab and daratumumab immune-based doublet therapy for relapsed/refractory multiple myeloma: the TRIMM-2 study

Blood Advances · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles